SEC23B is Very Rarely Studied in Cancer   Enters the nucleus and plays other roles

SEC23B is Very Rarely Studied in Cancer Enters the nucleus and plays other roles

Cancer-News

1 year
121 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Charis Eng, MD, PhD, Genomic Medicine Institute - Cleveland Clinic, explains SEC23B is Very Rarely Studied in Cancer Enters the nucleus and plays other roles at AACR 2018.
Up Next Autoplay
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Acute Lymphoblastic Leukemia
14 Views
kidneycancer 8 hours
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
1 Views
UVA Cancer Center 9 hours
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
2 Views
Cancer-News 12 hours
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
9 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
4 Views
CURC 1 day
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 1 day
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 1 day
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 1 day
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 1 day